Syed Ali-aamir Rizvi - Apr 1, 2024 Form 4 Insider Report for Poseida Therapeutics, Inc. (PSTX)

Role
Chief Medical Officer
Signature
/s/ Harry J.Leonhardt, Attorney-in-Fact
Stock symbol
PSTX
Transactions as of
Apr 1, 2024
Transactions value $
$0
Form type
4
Date filed
4/3/2024, 04:03 PM
Previous filing
Feb 23, 2023
Next filing
Jan 8, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PSTX Common Stock Award $0 +185K $0.00 185K Apr 1, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PSTX Employee Stock Option (Right to Buy) Award $0 +250K $0.00 250K Apr 1, 2024 Common Stock 250K $3.10 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's 2022 Inducement Plan. The RSUs are scheduled to vest in four equal annual installments.
F2 12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date, and the remaining shares will vest in 42 equal monthly installments thereafter.